These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 10501435)

  • 1. Interpreting the clinical significance of the differential inhibition of cyclooxygenase-1 and cyclooxygenase-2.
    Brooks P; Emery P; Evans JF; Fenner H; Hawkey CJ; Patrono C; Smolen J; Breedveld F; Day R; Dougados M; Ehrich EW; Gijon-Baños J; Kvien TK; Van Rijswijk MH; Warner T; Zeidler H
    Rheumatology (Oxford); 1999 Aug; 38(8):779-88. PubMed ID: 10501435
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The discovery and function of COX-2.
    Needleman P; Isakson PC
    J Rheumatol Suppl; 1997 Jul; 49():6-8. PubMed ID: 9249644
    [No Abstract]   [Full Text] [Related]  

  • 3. COX-1 and COX-2 inhibition: current status and future perspective.
    Greyn J; Lauwers MH; Vanlersberghe C; Camu F
    Acta Anaesthesiol Belg; 1998; 49(3):175-83. PubMed ID: 9844704
    [No Abstract]   [Full Text] [Related]  

  • 4. The role of COX-1 and COX-2 in asthma pathogenesis and its significance in the use of selective inhibitors.
    Szczeklik A; Sanak M
    Clin Exp Allergy; 2002 Mar; 32(3):339-42. PubMed ID: 11940059
    [No Abstract]   [Full Text] [Related]  

  • 5. Distinct isoforms (COX-1 and COX-2) of cyclooxygenase: possible physiological and therapeutic implications.
    Pairet M; Engelhardt G
    Fundam Clin Pharmacol; 1996; 10(1):1-17. PubMed ID: 8900495
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective cyclooxygenase-2 inhibitors as potential therapeutic agents for inflammatory diseases.
    Chan CC; Rodger IW
    Adv Exp Med Biol; 1997; 407():157-61. PubMed ID: 9321947
    [No Abstract]   [Full Text] [Related]  

  • 7. Pharmacology and clinical action of COX-2 selective NSAIDs.
    Bovill JG
    Adv Exp Med Biol; 2003; 523():201-14. PubMed ID: 15088852
    [No Abstract]   [Full Text] [Related]  

  • 8. [New NSAIDS: COX-1, COX-2, what about them?].
    Peretz A
    Rev Med Brux; 1998 Sep; 19(4):A399-402. PubMed ID: 9805982
    [TBL] [Abstract][Full Text] [Related]  

  • 9. COX-2 inhibitors: a review.
    Houston AM; Teach SJ
    Pediatr Emerg Care; 2004 Jun; 20(6):396-9; quiz 400-2. PubMed ID: 15179150
    [No Abstract]   [Full Text] [Related]  

  • 10. COX-2 inhibitors--is there cause for concern?
    Seibert K; Lefkowith J; Tripp C; Isakson P; Needleman P
    Nat Med; 1999 Jun; 5(6):621-2. PubMed ID: 10371498
    [No Abstract]   [Full Text] [Related]  

  • 11. Introduction: mechanism of action of NSAIDs.
    Vane JR
    Br J Rheumatol; 1996 Apr; 35 Suppl 1():1-3. PubMed ID: 8630629
    [No Abstract]   [Full Text] [Related]  

  • 12. Are COX-2 inhibitors as effective as conventional NSAIDs in acute pain states?
    Bannwarth B
    Arch Intern Med; 2001 Jan; 161(1):127-8. PubMed ID: 11146712
    [No Abstract]   [Full Text] [Related]  

  • 13. Cyclo-oxygenase isoenzymes: physiological and pharmacological role.
    Kam PC; See AU
    Anaesthesia; 2000 May; 55(5):442-9. PubMed ID: 10792135
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cox-2-selective inhibitors: the new super aspirins.
    DeWitt DL
    Mol Pharmacol; 1999 Apr; 55(4):625-31. PubMed ID: 10101019
    [No Abstract]   [Full Text] [Related]  

  • 15. [In vivo selectivity of nonsteroidal anti-inflammatory drugs on COX-1-COX-2 and gastrointestinal ulcers, in rats].
    Laudanno OM; Cesolari JA; Esnarriaga J; Flaherty P; Vada J; Guastalli G; San Miguel P; Bedini OA
    Acta Gastroenterol Latinoam; 1998; 28(3):249-55. PubMed ID: 9773153
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 4,5-Diaryloxazole inhibitors of cyclooxygenase-2 (COX-2).
    Talley JJ; Bertenshaw SR; Brown DL; Carter JS; Graneto MJ; Koboldt CM; Masferrer JL; Norman BH; Rogier DJ; Zwwifel BS; Seibert K
    Med Res Rev; 1999 May; 19(3):199-208. PubMed ID: 10232649
    [TBL] [Abstract][Full Text] [Related]  

  • 17. From indomethacin to a selective COX-2 inhibitor. Development of indolalkanoic acids as potent and selective cyclooxygenase-2 inhibitors.
    Lau CK; Black WC; Belley M; Chan C; Charleson S; Denis D; Gauthier JY; Gordon R; Guay D; Hamel P; Kargman S; Leblanc Y; Mancini J; Ouellet M; Percival D; Prasit P; Roy P; Skorey K; Tagari P; Vickers P; Wong E
    Adv Exp Med Biol; 1997; 407():73-8. PubMed ID: 9321934
    [No Abstract]   [Full Text] [Related]  

  • 18. Prime suspect.
    Manuel J
    Environ Health Perspect; 1997 Jan; 105(1):28-9. PubMed ID: 9074875
    [No Abstract]   [Full Text] [Related]  

  • 19. The development of COX2 inhibitors.
    Flower RJ
    Nat Rev Drug Discov; 2003 Mar; 2(3):179-91. PubMed ID: 12612644
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cyclooxygenase inhibition and thrombogenicity.
    Catella-Lawson F; Crofford LJ
    Am J Med; 2001 Feb; 110 Suppl 3A():28S-32S. PubMed ID: 11173047
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.